ArticleJournal of neuroengineering and rehabilitation2025
Non-invasive assessment of muscle spasticity in children with cerebral palsy undergoing botulinum toxin treatment using near-infrared spectroscopy.
Article in Journal of neuroengineering and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpasticity is a common and debilitating feature of cerebral palsy (CP), often treated with botulinum toxin A (BoNT-A). Standard assessments, such as the Modified Ashworth Scale (MAS), are subjective and prone to inter-rater variability. Near-infrared spectroscopy (NIRS) is a non-invasive method that measures muscle oxygenation and hemodynamics. In CP, spastic muscles exhibit impaired perfusion and abnormal oxygen consumption due to sustained contraction and elevated intramuscular pressure. Prior studies suggest that reducing spastic overactivity improves local tissue oxygenation, indicating that NIRS-derived metrics could objectively reflect spasticity severity and treatment response.
objectiveTo evaluate the feasibility of using NIRS as a biomarker for spasticity severity and treatment response in children with CP receiving BoNT-A and to assess the correlation between NIRS-derived tissue oxygenation index (TOI%) and MAS scores over time.
methodsIn this prospective pilot study, eight children (aged 2–17 years) with CP undergoing BoNT-A treatment were assessed. Muscle oxygenation was recorded using a portable NIRS device at baseline, 2–4 weeks, 6–10 weeks, 3 months, and 6 months post-injection. Spasticity was measured concurrently using MAS. Temporal changes in TOI% and MAS were analyzed using repeated-measures ANOVA, and associations between the two were evaluated with Pearson correlation.
resultsTOI% increased significantly after injection, peaking at 6–10 weeks and 3 months (p < 0.001), then declined toward baseline by 6 months. MAS scores showed a similar trend, with reduced spasticity during peak effect. A moderate, significant negative correlation between TOI% and MAS (r = − 0.409, p < 0.05) indicated higher oxygenation was associated with lower spasticity.
conclusionNIRS is a feasible, non-invasive tool for assessing muscle spasticity and monitoring BoNT-A response in children with CP. Its correlation with MAS supports physiological relevance and suggests NIRS may offer a more objective measure of spasticity. Larger studies are warranted to validate these findings and support clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.